{"contentid": 488223, "importid": NaN, "name": "Latest Pfizer-BioNTech results offer youthful optimism", "introduction": "There was further encouraging news on the vaccine front on Wednesday as Pfizer and BioNTech announced positive findings on their vaccine from a Phase III trial in adolescents.", "content": "<p>There was further encouraging news on the vaccine front on Wednesday as Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) announced positive findings on their vaccine from a Phase III trial in adolescents.</p>\n<p>In patients aged 12 to 15 years with or without prior evidence of SARS-CoV-2 infection, the Pfizer-BioNTech COVID-19 vaccine BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those recorded earlier in vaccinated participants aged 16 to 25 years old, and was well tolerated. These are topline results from a pivotal trial in 2,260 adolescents.</p>\n<p><span class=\"pullQuote\">\"The initial results we have seen in the adolescent studies suggest that children are particularly well-protected by vaccination\"</span>The vaccine, which is sold under the name Comirnaty, is already approved for adults in much of the world.</p>\n<p>Albert Bourla, chairman and chief executive, Pfizer, said: &ldquo;We share the urgency to expand the authorization of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15.</p>\n<p>&ldquo;We plan to submit these data to US Food and Drug Administration as a proposed amendment to our Emergency Use Authorization in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year.&rdquo;</p>\n<p>Ugur Sahin, chief executive and co-founder of BioNTech, said: &ldquo;Across the globe, we are longing for a normal life. This is especially true for our children. The initial results we have seen in the adolescent studies suggest that children are particularly well-protected by vaccination, which is very encouraging given the trends we have seen in recent weeks regarding the spread of the B117 UK variant.</p>\n<p>&ldquo;It is very important to enable them to get back to everyday school life and to meet friends and family while protecting them and their loved ones.&rdquo;</p>\n<p>Meanwhile, Pfizer and BioNTech dosed the first healthy children in a global Phase I/II/III seamless study last week to further evaluate the safety, tolerability, and immunogenicity of the vaccine in children six months to 11 years of age.</p>\n<p>The study is evaluating the safety, tolerability, and immunogenicity of the vaccine on a two-dose schedule approximately 21 days apart in three age groups: children aged five to 11 years, two to five years, and six months to two years. The five to 11 year-old cohort started dosing last week and the companies plan to initiate the two to five year-old cohort next week.</p>", "date": "2021-03-31 16:43:00", "meta_title": NaN, "meta_keywords": "vaccine, results, children, adolescents, trial, years, Pfizer, BioNTech, encouraging, Phase, Pfizer-BioNTech, Latest, youthful, optimism, offer, Wednesday", "meta_description": "There was further encouraging news on the vaccine front on Wednesday as Pfizer and BioNTech announced positive findings on their vaccine from a Phase III trial ", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-31 16:34:35", "updated": "2021-03-31 17:03:16", "access": NaN, "url": "https://www.thepharmaletter.com/article/latest-pfizer-biontech-results-offer-youthful-optimism", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "biontech_vaccine_large.jpg", "image2id": "biontech_vaccine_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Drug Trial, Focus On, Research", "geography_tag": "Germany, USA", "company_tag": "BioNTech, Pfizer", "drug_tag": "Comirnaty", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-31 16:43:00"}